Page 2290 - Williams Hematology ( PDFDrive )

2264 Part XII: Hemostasis and Thrombosis Chapter 132: Thrombotic Microangiopathies 2265

99. Lewis QF, Lanneau MS, Mathias SD, et al: Long-term deficits in health-related quality 129. Braune SA, Wichmann D, von Heinz MC, et al: Clinical features of critically ill patients
of life after recovery from thrombotic thrombocytopenic purpura. Transfusion 49:118, with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med 41:1702, 2013.
2009. 130. Garg AX, Suri RS, Barrowman N, et al: Long-term renal prognosis of diarrhea-
100. Hayward CP, Sutton DM, Carter WH Jr, et al: Treatment outcomes in patients with associated hemolytic uremic syndrome: A systematic review, meta-analysis, and
adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern meta- regression. JAMA 290:1360, 2003.
Med 154:982, 1994. 131. Barnard PJ, Kibel M: The haemolytic-uraemic syndrome of infancy and childhood.
101. Coppo P, Bengoufa D, Veyradier A, et al: Severe ADAMTS13 deficiency in adult idio- A report of eleven cases. Cent Afr J Med 11:31, 1965.
pathic thrombotic microangiopathies defines a subset of patients characterized by 132. Kaplan BS, Chesney RW, Drummond KN: Hemolytic uremic syndrome in families.
various autoimmune manifestations, lower platelet count, and mild renal involvement. N Engl J Med 292:1090, 1975.
Medicine (Baltimore) 83:233, 2004. 133. Kaplan BS: Hemolytic uremic syndrome with recurrent episodes: An important subset.
102. Schulman I, Pierce M, Lukens A, Currimbhoy Z: Studies on thrombopoiesis. I. A factor Clin Nephrol 8:495, 1977.
in normal human plasma required for platelet production; chronic thrombocytopenia 134. Fitzpatrick MM, Walters MD, Trompeter RS, et al: Atypical (non-diarrhea-associated)
due to its deficiency. Blood 16:943, 1960. hemolytic-uremic syndrome in childhood. J Pediatr 122:532, 1993.
103. Upshaw JD Jr: Congenital deficiency of a factor in normal plasma that reverses 135. Thompson RA, Winterborn MH: Hypocomplementaemia due to a genetic deficiency of
microangiopathic hemolysis and thrombocytopenia. N Engl J Med 298:1350, 1978. beta 1H globulin. Clin Exp Immunol 46:110, 1981.
104. Zheng XL, Sadler JE: Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 136. Warwicker P, Goodship TH, Donne RL, et al: Genetic studies into inherited and
3:249, 2008. sporadic hemolytic uremic syndrome. Kidney Int 53:836, 1998.
105. Furlan M, Lämmle B: Aetiology and pathogenesis of thrombotic thrombocytopenic 137. Legendre CM, Licht C, Muus P, et al: Terminal complement inhibitor eculizumab in
purpura and haemolytic uraemic syndrome: The role of von Willebrand factor-cleaving atypical hemolytic-uremic syndrome. N Engl J Med 368:2169, 2013.
protease. Best Pract Res Clin Haematol 14:437, 2001. 138. Noris M, Caprioli J, Bresin E, et al: Relative role of genetic complement abnormalities
106. Miyata T, Kokame K, Matsumoto M, Fujimura Y: ADAMTS13 activity and genetic in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc
mutations in Japan. Hamostaseologie 33:131, 2013. Nephrol 5:1844, 2010.
107. Loirat C, Girma JP, Desconclois C, et al: Thrombotic thrombocytopenic purpura related 139. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al: Genetics and outcome of atypical
to severe ADAMTS13 deficiency in children. Pediatr Nephrol 24:19, 2009. hemolytic uremic syndrome: A nationwide French series comparing children and
108. Veyradier A, Meyer D, Loirat C: Desmopressin, an unexpected link between noctur- adults. Clin J Am Soc Nephrol 8:554, 2013.
nal enuresis and inherited thrombotic thrombocytopenic purpura (Upshaw-Schulman 140. Lemaire M, Fremeaux-Bacchi V, Schaefer F, et al: Recessive mutations in DGKE cause
syndrome). J Thromb Haemost 4:700, 2006. atypical hemolytic-uremic syndrome. Nat Genet 45:531, 2013.
109. Scully M, Thomas M, Underwood M, et al: Thrombotic thrombocytopenic purpura and 141. Taylor CM, Machin S, Wigmore SJ, et al: Clinical practice guidelines for the manage-
pregnancy: Presentation, management, and subsequent pregnancy outcomes. Blood ment of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol
124:211, 2014. 148:37, 2010.
110. Raval JS, Padmanabhan A, Kremer Hovinga JA, Kiss JE: Development of a clinically 142. Fakhouri F, Roumenina L, Provot F, et al: Pregnancy-associated hemolytic uremic syn-
significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocy- drome revisited in the era of complement gene mutations. J Am Soc Nephrol 21:859,
topenic purpura. Am J Hematol 90:E22, 2015. 2010.
111. Wallace DC, Lovric A, Clubb JS, Carseldine DB: Thrombotic thrombocytopenic 143. Rossio R, Lotta LA, Pontiggia S, et al: A novel CD46 mutation in a patient with
purpura in four siblings. Am J Med 58:724, 1975. microangiopathy clinically resembling thrombotic thrombocytopenic purpura and
112. Furlan M, Robles R, Morselli B, et al: Recovery and half-life of von Willebrand factor- normal ADAMTS13 activity. Haematologica 100:e87, 2015.
cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic 144. Noris M, Remuzzi G: Managing and preventing atypical hemolytic uremic syndrome
purpura. Thromb Haemost 81:8, 1999. recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 22:704, 2013.
113. Lotta LA, Wu HM, Mackie IJ, et al: Residual plasmatic activity of ADAMTS13 is cor- 145. Sanchez Chinchilla D, Pinto S, Hoppe B, et al: Complement mutations in diacylglycerol
related with phenotype severity in congenital thrombotic thrombocytopenic purpura. kinase-epsilon-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol
Blood 120:440, 2012. 9:1611, 2014.
114. Camilleri RS, Scully M, Thomas M, et al: A phenotype-genotype correlation of 146. Westland R, Bodria M, Carrea A, et al: Phenotypic expansion of DGKE-associated
ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients diseases. J Am Soc Nephrol 25:1408, 2014.
treated in the United Kingdom. J Thromb Haemost 10:1792, 2012. 147. Cabrera GR, Fortenberry JD, Warshaw BL, et al: Hemolytic uremic syndrome associ-
115. Gasser C, Gautier E, Steck A, et al: Hämolytisch-ürämische Syndrome: Bilaterale ated with invasive Streptococcus pneumoniae infection. Pediatrics 101:699, 1998.
Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med 148. Copelovitch L, Kaplan BS: Streptococcus pneumoniae-associated hemolytic uremic
Wochenschr 85:905, 1955. syndrome. Pediatr Nephrol 23:1951, 2008.
116. Kibel MA, Barnard PJ: The haemolytic-uraemic syndrome: A survey in Southern 149. Singh N, Gayowski T, Marino IR: Hemolytic uremic syndrome in solid-organ trans-
Africa. S Afr Med J 42:692, 1968. plant recipients. Transpl Int 9:68, 1996.
117. Karmali MA, Steele BT, Petric M, Lim C: Sporadic cases of haemolytic-uraemic 150. Arai S, Allan C, Streiff M, et al: Von Willebrand factor-cleaving protease activity and
syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic
stools. Lancet 1:619, 1983. microangiopathy. Hematol J 2:292, 2001.
118. O’Brien AO, Lively TA, Chen ME, et al: Escherichia coli O157:H7 strains associated with 151. Ho VT, Cutler C, Carter S, et al: Blood and marrow transplant clinical trials network
haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like toxicity committee consensus summary: Thrombotic microangiopathy after hemato-
cytotoxin. Lancet 1:702, 1983. poietic stem cell transplantation. Biol Blood Marrow Transplant 11:571, 2005.
119. Riley LW, Remis RS, Helgerson SD, et al: Hemorrhagic colitis associated with a rare 152. Sack GH Jr, Levin J, Bell WR: Trousseau’s syndrome and other manifestations of chronic
Escherichia coli serotype. N Engl J Med 308:681, 1983. disseminated coagulopathy in patients with neoplasms: Clinical, pathophysiologic, and
120. Tarr PI, Gordon CA, Chandler WL: Shiga-toxin-producing Escherichia coli and haemo- therapeutic features. Medicine (Baltimore) 56:1, 1977.
lytic uraemic syndrome. Lancet 365:1073, 2005. 153. Elliott MA, Letendre L, Gastineau DA, et al: Cancer-associated microangiopathic
121. Gianviti A, Tozzi AE, De Petris L, et al: Risk factors for poor renal prognosis in children hemolytic anemia with thrombocytopenia: An important diagnostic consideration. Eur
with hemolytic uremic syndrome. Pediatr Nephrol 18:1229, 2003. J Haematol 85:43, 2010.
122. Frank C, Werber D, Cramer JP, et al: Epidemic profile of Shiga-toxin-producing Escher- 154. Domingo-Claros A, Larriba I, Rozman M, et al: Acute erythroid neoplastic prolifera-
ichia coli O104:H4 outbreak in Germany. N Engl J Med 365:1771, 2011. tions. A biological study based on 62 patients. Haematologica 87:148, 2002.
123. Proesmans W: The role of coagulation and fibrinolysis in the pathogenesis of diar- 155. Lattuada A, Rossi E, Calzarossa C, et al: Mild to moderate reduction of a von Wille-
rhea-associated hemolytic uremic syndrome. Semin Thromb Hemost 27:201, 2001. brand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP
124. Tsai HM, Chandler WL, Sarode R, et al: Von Willebrand factor and von Willebrand fac- microangiopathic syndrome. Haematologica 88:1029, 2003.
tor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic 156. Baron BW, Martin MS, Sucharetza BS, et al: Four patients with both thrombotic throm-
uremic syndrome. Pediatr Res 49:653, 2001. bocytopenic purpura and autoimmune thrombocytopenic purpura: The concept of a
125. Hunt BJ, Lämmle B, Nevard CH, et al: Von Willebrand factor-cleaving protease in mixed immune thrombocytopenia syndrome and indications for plasma exchange.
childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost J Clin Apher 16:179, 2001.
85:975, 2001. 157. Mannucci PM, Vanoli M, Forza I, et al: Von Willebrand factor cleaving protease
126. Inward CD, Howie AJ, Fitzpatrick MM, et al: Renal histopathology in fatal cases of (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythe-
diarrhoea-associated haemolytic uraemic syndrome. British Association for Paediatric matosus and systemic sclerosis). Haematologica 88:914, 2003.
Nephrology. Pediatr Nephrol 11:556, 1997. 158. Güngör T, Furlan M, Lämmle B, et al: Acquired deficiency of von Willebrand
127. Wong CS, Mooney JC, Brandt JR, et al: Risk factors for the hemolytic uremic syndrome factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus.
in children infected with Escherichia coli O157:H7: A multivariable analysis. Clin Infect Rheumatology (Oxford) 40:940, 2001.
Dis 55:33, 2012. 159. Ahmed S, Siddiqui AK, Chandrasekaran V: Correlation of thrombotic thrombocy-
128. Menne J, Nitschke M, Stingele R, et al: Validation of treatment strategies for entero- topenic purpura disease activity with von Willebrand factor-cleaving protease level in
haemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: ulcerative colitis. Am J Med 116:786, 2004.
Case-control study. BMJ 345:e4565, 2012. 160. Steen VD: Scleroderma renal crisis. Rheum Dis Clin North Am 29:315, 2003.

Kaushansky_chapter 132_p2253-2266.indd 2265 17/09/15 3:48 pm